StocksMedium•9 November 2026•
1 min read
Eli Lilly Stock Rises on Canadian Approval for Alzheimer's Drug Reimbursement
Key Facts
1Eli Lilly stock rose after its Alzheimer’s drug received approval for public reimbursement in Canada.
Eli Lilly stock rose after its Alzheimer’s drug received approval for public reimbursement in Canada. TipRanks reported that the regulatory milestone triggered a positive reaction in the company's share price, as the move expands the accessible patient base in a major international market.
LLY closed at $1354 on November 6, 2026, prior to the announcement of the Canadian reimbursement approval. The stock traded between a session low of $1333.22 and a high of $1377.28 on that date, reflecting the equity's price action leading into this latest pharmaceutical development.